The Role of Gut Microbiota as a Trigger for Exacerbations in Pulmonary Obstruction Disorder in General
Downloads
Pulmonary diseases can be associated with the gastrointestinal (GI) system, particularly if an infection causes them. This relationship between organs is known as the gut-lung axis (GLA). Skin and mucosal surfaces are associated with microbiota (bacteria, fungi, viruses, macrophages, archaea, protists, helminths), which can trigger an immune response in GLA and serve a role in respiratory diseases. For instance, asthma can be inhibited by a specific antigen that is triggered by probiotics, the microorganisms found in the GI tract. Asthma incidence can be reduced by consuming fiber due to its ability to protect airways from infection. Pattern recognition receptors (PRRs) are the first immune component to identify microbial compounds in GI and lung epithelial cells. The PRRs then induce regulatory T-cell (T-reg) and Th-17 differentiation. Diet, antibiotics, and stress can all influence the structure and function of bacteria. This is known as dysbiosis. Lung microbiota can influence immune cell maturation and homeostasis. If the diversity of lung microbiota decreases, it will affect intestinal microbiota and may result in chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. This literature review explained how the interactions between the intestines and lungs can affect humans’ health and well-being.
Gilbert JA, Blaser MJ, Caporaso JG, et al. Current Understanding of the Human Microbiome. Nat Med 2018; 24: 392–400. [PubMed]
Rastogi S, Singh A. Gut Microbiome and Human Health: Exploring How the Probiotic Genus Lactobacillus Modulate Immune Responses. Front Pharmacol 2022; 13: 1042189. [PubMed]
Chunxi L, Haiyue L, Yanxia L, et al. The Gut Microbiota and Respiratory Diseases: New Evidence. J Immunol Res 2020; 2020: 2340670. [PubMed]
Zhuang Y, Ding T, Zhao J, et al. Editorial: Respiratory Microbiome in Health and Disease. Frontiers in Cellular and Infection Microbiology 2023; 13: 1335337. [PubMed]
Liu BN, Liu XT, Liang ZH, et al. Gut Microbiota in Obesity. World J Gastroenterol 2021; 27: 3837–3850. [PubMed]
Shah T, Baloch Z, Shah Z, et al. The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases. Int J Mol Sci; 22. Epub ahead of print June 2021. [PubMed]
Natalini JG, Singh S, Segal LN. The Dynamic Lung Microbiome in Health and Disease. Nat Rev Microbiol 2023; 21: 222–235. [PubMed]
Frati F, Salvatori C, Incorvaia C, et al. The Role of the Microbiome in Asthma: The Gut−Lung Axis. Int J Mol Sci; 20. Epub ahead of print December 2018. [PubMed]
Mitre E, Susi A, Kropp LE, et al. Association between Use of Acid-Suppressive Medications and Antibiotics during Infancy and Allergic Diseases in Early Childhood. JAMA Pediatr 2018; 172: e180315. [PubMed]
Narayana JK, Aliberti S, Mac Aogáin M, et al. Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis. Am J Respir Crit Care Med 2023; 207: 908–920. [PubMed]
Enaud R, Prevel R, Ciarlo E, et al. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks. Front Cell Infect Microbiol 2020; 10: 9. [PubMed]
Mitchell AB, Glanville AR. Introduction to Techniques and Methodologies for Characterizing the Human Respiratory Virome. Methods Mol Biol 2018; 1838: 111–123. [PubMed]
Zhang D, Li S, Wang N, et al. The Cross-Talk between Gut Microbiota and Lungs in Common Lung Diseases. Front Microbiol 2020; 11: 301. [PubMed]
Blanco-Pérez F, Steigerwald H, Schülke S, et al. The Dietary Fiber Pectin: Health Benefits and Potential for the Treatment of Allergies by Modulation of Gut Microbiota. Curr Allergy Asthma Rep 2021; 21: 43. [PubMed]
Bulanda E, Wypych TP. Bypassing the Gut-Lung Axis via Microbial Metabolites: Implications for Chronic Respiratory Diseases. Front Microbiol 2022; 13: 857418. [PubMed]
Fu G, Zhao K, Chen H, et al. Effect of 3 Lactobacilli on Immunoregulation and Intestinal Microbiota in a β-Lactoglobulin-Induced Allergic Mouse Model. J Dairy Sci 2019; 102: 1943–1958. [PubMed]
Yang W, Ansari AR, Niu X, et al. Interaction between Gut Microbiota Dysbiosis and Lung Infection as Gut-Lung Axis caused by Streptococcus suis in Mouse Model. Microbiol Res 2022; 261: 127047. [PubMed]
Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Postbiotics. Nat Rev Gastroenterol Hepatol 2021; 18: 649–667. [PubMed]
Cleophas MCP, Ratter JM, Bekkering S, et al. Effects of Oral Butyrate Supplementation on Inflammatory Potential of Circulating Peripheral Blood Mononuclear Cells in Healthy and Obese Males. Sci Rep 2019; 9: 775. [PubMed]
Li M, van Esch BCAM, Wagenaar GTM, et al. Pro- and Anti-Inflammatory Effects of Short Chain Fatty Acids on Immune and Endothelial Cells. Eur J Pharmacol 2018; 831: 52–59. [PubMed]
Dang AT, Marsland BJ. Microbes, Metabolites, and the Gut-Lung Axis. Mucosal Immunol 2019; 12: 843–850. [PubMed]
Wypych TP, Wickramasinghe LC, Marsland BJ. The Influence of the Microbiome on Respiratory Health. Nat Immunol 2019; 20: 1279–1290. [PubMed]
Liu X, Shao J, Liao Y-T, et al. Regulation of Short-Chain Fatty Acids in the Immune System. Front Immunol; 14, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1186892 (2023).
Trivedi R, Barve K. Gut Microbiome a Promising Target for Management of Respiratory Diseases. Biochem J 2020; 477: 2679–2696. [PubMed]
Zheng D, Liwinski T, Elinav E. Interaction between Microbiota and Immunity in Health and Disease. Cell Res 2020; 30: 492–506. [PubMed]
Le Guern R, Grandjean T, Stabler S, et al. Gut Colonisation with Multidrug-Resistant Klebsiella pneumoniae Worsens Pseudomonas aeruginosa Lung Infection. Nat Commun 2023; 14: 78. [PubMed]
Haller D. The Gut Microbiome in Health and Disease. 2018. Epub ahead of print 1 January 2018. [Springer]
Wang X, Lin X, Zheng Z, et al. Host-Derived Lipids Orchestrate Pulmonary γδ T Cell Response to Provide Early Protection against Influenza Virus Infection. Nat Commun 2021; 12: 1914. [PubMed]
Liu C, Makrinioti H, Saglani S, et al. Microbial Dysbiosis and Childhood Asthma Development: Integrated Role of the Airway and Gut Microbiome, Environmental Exposures, and Host Metabolic and Immune Response. Front Immunol; 13, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1028209 (2022).
Dumas A, Bernard L, Poquet Y, et al. The Role of the Lung Microbiota and the Gut-Lung Axis in Respiratory Infectious Diseases. Cell Microbiol 2018; 20: e12966. [PubMed]
Khan R, Petersen FC, Shekhar S. Commensal Bacteria: An Emerging Player in Defense Against Respiratory Pathogens. Front Immunol 2019; 10: 1203. [PubMed]
Li N, Dai Z, Wang Z, et al. Gut Microbiota Dysbiosis Contributes to the Development of Chronic Obstructive Pulmonary Disease. Respir Res 2021; 22: 274. [PubMed]
Ahn SV, Lee E, Park B, et al. Cancer Development in Patients with COPD: A Retrospective Analysis of the National Health Insurance Service-National Sample Cohort in Korea. BMC Pulm Med 2020; 20: 170. [PubMed]
Wang L, Cai Y, Garssen J, et al. The Bidirectional Gut-Lung Axis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2023; 207: 1145–1160. [PubMed]
Yadav RS, Kant S, Tripathi PM, et al. Transcription Factor NF-κB, Interleukin-1β, and Interleukin-8 Expression and Its Association with Tobacco Smoking and Severity in Chronic Obstructive Pulmonary Disease. Gene Reports 2022; 26: 101453. [ScienceDirect]
Mammen MJ, Scannapieco FA, Sethi S. Oral-Lung Microbiome Interactions in Lung Diseases. Periodontol 2000 2020; 83: 234–241. [PubMed]
Raftery AL, Tsantikos E, Harris NL, et al. Links between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease. Front Immunol 2020; 11: 2144. [PubMed]
Schluter J, Peled JU, Taylor BP, et al. The Gut Microbiota is Associated with Immune Cell Dynamics in Humans. Nature 2020; 588: 303–307. [PubMed]
Kallio S, Kukkonen AK, Savilahti E, et al. Perinatal Probiotic Intervention Prevented Allergic Disease in a Caesarean-Delivered Subgroup at 13-Year Follow-Up. Clin Exp Allergy 2019; 49: 506–515. [PubMed]
Skalski JH, Limon JJ, Sharma P, et al. Expansion of Commensal Fungus Wallemia mellicola in the Gastrointestinal Mycobiota Enhances the Severity of Allergic Airway Disease in Mice. PLoS Pathog 2018; 14: e1007260. [PubMed]
Magee LC, Louis M, Khan V, et al. Managing Fungal Infections in Cystic Fibrosis Patients: Challenges in Clinical Practice. Infect Drug Resist 2021; 14: 1141–1153. [PubMed]
Mahooti M, Abdolalipour E, Salehzadeh A, et al. Immunomodulatory and Prophylactic Effects of Bifidobacterium bifidum Probiotic Strain on Influenza Infection in Mice. World J Microbiol Biotechnol 2019; 35: 91. [PubMed]
Van Biervliet S, Hauser B, Verhulst S, et al. Probiotics in Cystic Fibrosis Patients: A Double Blind Crossover Placebo Controlled Study: Pilot Study from the ESPGHAN Working Group on Pancreas/CF. Clin Nutr ESPEN 2018; 27: 59–65. [PubMed]
Coffey MJ, Garg M, Homaira N, et al. Probiotics for People with Cystic Fibrosis. Cochrane Database Syst Rev 2020; 1: CD012949. [PubMed]
Mortaz E, Adcock IM, Ricciardolo FLM, et al. Anti-Inflammatory Effects of Lactobacillus rahmnosus and Bifidobacterium breve on Cigarette Smoke Activated Human Macrophages. PLoS One 2015; 10: e0136455. [PubMed]
Le Noci V, Guglielmetti S, Arioli S, et al. Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Rep 2018; 24: 3528–3538. [PubMed]
Li R, Li J, Zhou X. Lung Microbiome: New Insights into the Pathogenesis of Respiratory Diseases. Signal Transduct Target Ther 2024; 9: 19. [PubMed]
Labaki WW, Rosenberg SR. Chronic Obstructive Pulmonary Disease. Ann Intern Med 2020; 173: ITC17–ITC32. [PubMed]
Copyright (c) 2024 Dewi Wijaya, Elvando Tunggul Mauliate Simatupang, Yolanda Julia Perel Putri, Adelia Pratiwi, Shaogi Syam, Dewi Anggraini
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.